ZED-1227 is a specific and orally active transglutaminase 2 (TG2) inhibitor, with an IC 50 of 45 nM. ZED-1227 can block inflammation-induced TG2 expression and activity. ZED-1227 can be used for the research of celiac disease (CeD).
性状
Solid
IC50 & Target[1][2]
IC50: 45 nM (TG2)
体外研究(In Vitro)
ZED-1227 (0.1 μΜ-1 μΜ; 24 hours) has no effect on metabolic activity and proliferation in Huh7 cells and CaCo2 cells, that suggests ZED-1227 has no cytotoxic activity.ZED-1227 (0.002-0.2 mg/mL; 30 minutes) inhibits TG2 in the small intestinal mucosa in vitro. has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究(In Vivo)
ZED-1227 reduces the activity of intestinal TG2 induced by Polyinosinic:Polycytidylic acid (40 mg/kg) to normal control levels and subdues intestinal inflammation in mice.
ZED-1227 (5 mg/kg; i.g.) is able to inhibit TG2 in the small intestinal mucosa. has not independently confirmed the accuracy of these methods. They are for reference only.
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years;4°C 2 years
ClinicalTrial
参考文献
[1]. Manu Encalada, et al. The Oral Transglutaminase 2 (TG2) Inhibitor Zed1227 Blocks TG2 Activity in a Mouse Model of Intestinal Inflammation. Gastroenterology. 154(6):S-490.[2]. Christian Büchold, et al. Pyridinone derivatives as tissue transglutaminase inhibitors. WO2014012858A1.
溶解度数据
In Vitro: DMSO : 125 mg/mL (236.47 mM; Need ultrasonic)配制储备液